Author

C. D. McFarland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Evolutionary Biology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:ecology & biodiversity· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

D. Petrov· 2 shared A. Durmaz· 1 shared C. Curtis· 1 shared C. Li· 1 shared C. M. Rudin· 1 shared D. S. Tadele· 1 shared H. Cai· 1 shared H. Rizvi· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersEvolutionary Biology

D. Petrov

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Frequency-dependent ecological interactions increase the prevalence and shape the distribution of pre-existing drug resistance

J. Maltas, D. S. Tadele, A. Durmaz, C. D. McFarland, M. Hinczewski, J. G. Scott

This study shows frequency-dependent ecological interactions help pre-existing drug resistance persist despite fitness costs, using simulations and engineered mutants in NSCLC.

bioRxiv · Mar 16, 2023 · PreprintEvolutionary Biology

Most cancers carry a substantial deleterious load due to Hill-Robertson interference

S. Tilk, C. Curtis, D. Petrov, C. D. McFarland

This study shows that most cancers do not remove deleterious mutations due to Hill-Robertson interference, leading to a 40% average fitness cost per cell.

bioRxiv · Feb 24, 2021Evolutionary Biology

Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

C. Li, W.-Y. Lin, H. Rizvi, H. Cai, C. D. McFarland, Z. N. Rogers, M. Yousefi, I. P. Winters, C. M. Rudin, D. Petrov, M. M. Winslow

The paper uses a quantitative platform and statistical methods to map pharmacogenomic responses in lung cancer, revealing complex genotype-specific therapeutic interactions.

bioRxiv · Jan 28, 2020Cancer Biology